Senestech (NASDAQ:SNES) versus Stagezero Life Sciences (OTCMKTS:SZLSF) Financial Analysis

Stagezero Life Sciences (OTCMKTS:SZLSF) and Senestech (NASDAQ:SNES) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Profitability

This table compares Stagezero Life Sciences and Senestech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stagezero Life Sciences	N/A	N/A	N/A
Senestech	-253.54%	-98.35%	-73.17%

Analyst Recommendations

This is a summary of current recommendations for Stagezero Life Sciences and Senestech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stagezero Life Sciences	0	0	0	0	0.00
Senestech	1	1	0	1	2.33

Insider & Institutional Ownership

5.2% of Senestech shares are owned by institutional investors. 2.5% of Stagezero Life Sciences shares are owned by insiders. Comparatively, 5.3% of Senestech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Stagezero Life Sciences has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Senestech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Earnings and Valuation

This table compares Stagezero Life Sciences and Senestech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stagezero Life Sciences	N/A	N/A	N/A	($0.01)	-0.05
Senestech	$1.86 million	5.73	-$6.18 million	($3.65)	-0.56

Stagezero Life Sciences has higher earnings, but lower revenue than Senestech. Senestech is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Senestech beats Stagezero Life Sciences on 6 of the 11 factors compared between the two stocks.

About Stagezero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

About Senestech

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.